Identification of royal jelly as a potential new drug to protect the ovarian reserve and uterus against cyclophosphamide in rats
- Author:
Mehmet BULBUL
1
;
Ali TEKCE
;
Ebru ANNAC
;
Omer KORKMAZ
;
Muhittin ONDERCI
;
Deniz KORKMAZ
;
Akin Mustafa DEMIRCI
Author Information
- Publication Type:Original Article
- From:Clinical and Experimental Reproductive Medicine 2023;50(1):34-43
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:The aim of this study was to investigate the effect of royal jelly (RJ), a powerful natural antioxidant, on cyclophosphamide-induced ovarian damage.
Methods:Thirty-two Wistar albino rats were divided into four groups. Oral treatment was administered to all rats for 16 days after a single intraperitoneal injection. The control group received intraperitoneal and oral saline; the RJ group received intraperitoneal saline and 100 mg/kg/day oral RJ; the cyclophosphamide group received intraperitoneal 100 mg/kg cyclophosphamide and oral saline; and the treatment group received intraperitoneal 100 mg/kg cyclophosphamide and 100 mg/kg/day oral RJ. The groups were compared in terms of ovarian reserve tests and histopathological changes in the ovary and uterus.
Results:All follicle counts were higher in the treatment group than in the cyclophosphamide group. The increase in the number of preantral follicles (p=0.001) and the decrease in the number of atretic follicles (p=0.004) were statistically significant. RJ treatment significantly improved follicular degeneration and cortical fibrosis in the ovary and epithelial and gland degeneration in the uterus due to cyclophosphamide toxicity.
Conclusion:According to these results, RJ reduces cyclophosphamide-related ovarian and endometrial damage in rats. For this reason, it should be further investigated to determine its effects on reproductive function.
